Warning letter

Horizon Pharmaceuticals, Inc.: warning letter of Dec 23, 2016

FDA warning letter 485363 · Florida District Office

Key facts

Reference number 485363
Company Horizon Pharmaceuticals, Inc.
Subject CGMP/Finished Pharmaceuticals/Adulterated
Issue date Dec 23, 2016
Posted date Jan 17, 2017
Issuing office Florida District Office
Product type Drugs
CFR sections cited 211.34, 211.192, 211.113(b), 211.160(b)
Inspection city Riviera Beach
Inspection ZIP 33404
Inspection start date Oct 27, 2015
Letter on fda.gov web.archive.org

At a glance

  • 1–9 CFR sections cited
  • OAI Linked inspection classification
  • Yes Form FDA 483 issued

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA warning letters

FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.

Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date:

Browse all FDA warning letters